Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

Posted by Defense World Staff on May 30th, 2023

Connor Clark & Lunn Investment Management Ltd. boosted its stake in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating) by 4.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,223 shares of the biopharmaceutical company’s stock after buying an additional 6,030 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.34% of Intercept Pharmaceuticals worth $1,759,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ICPT. Cheyne Capital Management UK LLP acquired a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at $327,000. Advisor Group Holdings Inc. grew its holdings in Intercept Pharmaceuticals by 255.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 45,899 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 32,968 shares during the period. Jupiter Asset Management Ltd. grew its holdings in Intercept Pharmaceuticals by 23.0% during the fourth quarter. Jupiter Asset Management Ltd. now owns 421,595 shares of the biopharmaceutical company’s stock worth $5,215,000 after acquiring an additional 78,954 shares during the period. Principal Financial Group Inc. grew its holdings in Intercept Pharmaceuticals by 16.0% during the fourth quarter. Principal Financial Group Inc. now owns 22,948 shares of the biopharmaceutical company’s stock worth $284,000 after acquiring an additional 3,157 shares during the period. Finally, Prospera Financial Services Inc grew its holdings in Intercept Pharmaceuticals by 10.1% during the fourth quarter. Prospera Financial Services Inc now owns 31,806 shares of the biopharmaceutical company’s stock worth $393,000 after acquiring an additional 2,916 shares during the period. 81.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ICPT shares. Bank of America lowered their target price on Intercept Pharmaceuticals from $17.00 to $14.00 in a report on Tuesday, May 23rd. Needham & Company LLC lowered Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Royal Bank of Canada lifted their target price on Intercept Pharmaceuticals from $17.00 to $19.00 and gave the stock a “sector perform” rating in a report on Friday, March 3rd. HC Wainwright lowered Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $8.00 target price on the stock. in a report on Monday, May 22nd. Finally, SVB Securities increased their price target on Intercept Pharmaceuticals from $17.00 to $18.00 in a research report on Friday, March 3rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $23.27.

Intercept Pharmaceuticals Trading Up 5.2 %

Shares of NASDAQ ICPT opened at $10.26 on Tuesday. Intercept Pharmaceuticals, Inc. has a one year low of $8.82 and a one year high of $21.86. The firm has a market capitalization of $427.74 million, a PE ratio of 1.63 and a beta of 1.25. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 3.32. The business has a 50-day moving average price of $14.93 and a two-hundred day moving average price of $15.87.

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) last announced its quarterly earnings data on Thursday, March 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The business had revenue of $77.22 million for the quarter, compared to analyst estimates of $76.89 million. As a group, analysts predict that Intercept Pharmaceuticals, Inc. will post -1.75 earnings per share for the current fiscal year.

Intercept Pharmaceuticals Company Profile

(Get Rating)

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.